TipRanks
BeOne Medicines (DE:49BA)
FRANKFURT:49BA
Germany Market
49BA
BeOne Medicines
RESEARCH TOOLSreports

BeOne Medicines (49BA) Stock Forecast & Price Target

4 Followers
See the Price Targets and Ratings of:

49BA Analyst Ratings

Strong Buy
14Ratings
Strong Buy
14 Buy
0 Hold
0 Sell
Based on 14 analysts giving stock ratings to
BeOne
Medicines
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

49BA Stock 12 Month Forecast

Average Price Target

€369.44
▲(16.18% Upside)
Based on 14 Wall Street analysts offering 12 month price targets for BeOne Medicines in the last 3 months. The average price target is €369.44 with a high forecast of €409.67 and a low forecast of €325.28. The average price target represents a 16.18% change from the last price of €318.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"239":"€239","410":"€410","281.75":"€281.8","324.5":"€324.5","367.25":"€367.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":409.6746499,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€409.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":369.4425144854643,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€369.44</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":325.2781555,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€325.28</span>\n  </div></div>","useHTML":true}}],"tickPositions":[239,281.75,324.5,367.25,410],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,302,310.2826653769231,318.5653307538462,326.8479961307692,335.1306615076923,343.4133268846154,351.6959922615385,359.9786576384615,368.2613230153846,376.5439883923077,384.8266537692308,393.1093191461539,401.391984523077,{"y":409.6746499,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,302,307.1878857296511,312.3757714593022,317.5636571889533,322.7515429186044,327.9394286482555,333.1273143779066,338.3152001075577,343.5030858372088,348.6909715668599,353.878857296511,359.0667430261621,364.2546287558132,{"y":369.4425144854643,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,302,303.7906273461538,305.5812546923077,307.37188203846154,309.1625093846154,310.95313673076924,312.74376407692307,314.53439142307695,316.3250187692308,318.1156461153846,319.9062734615385,321.6969008076923,323.4875281538462,{"y":325.2781555,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":270,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":288,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":270,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":288,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":258,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":284,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":260,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":262,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":246,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":240,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":248,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":272,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":302,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€409.67Average Price Target€369.44Lowest Price Target€325.28
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on DE:49BA
Etzer Darout
Barclays
Barclays
€357.81→€364.84
Buy
14.73%
Upside
Reiterated
09/10/26
Barclays Reaffirms Their Buy Rating on BeOne Medicines (ONC)
RBC Capital Analyst forecast on DE:49BA
Leonid Timashev
RBC Capital
RBC Capital
€395.61
Buy
24.41%
Upside
Reiterated
08/25/26
Analysts Offer Insights on Healthcare Companies: GE Healthcare Technologies Inc (NASDAQ: GEHC), Biogen (NASDAQ: BIIB) and BeOne Medicines (NASDAQ: ONC)
Wolfe Research Analyst forecast on DE:49BA
Kalpit Patel
Wolfe Research
Wolfe Research
€298.9→€325.28
Buy
2.29%
Upside
Assigned
08/09/26
BeOne Medicines price target raised to $370 from $340 at Wolfe ResearchBeOne Medicines price target raised to $370 from $340 at Wolfe Research
CMB International Securities Analyst forecast on DE:49BA
Jill Wu
CMB International Securities
CMB International Securities
€345→€388.85
Buy
22.28%
Upside
Reiterated
08/07/26
Analysts Conflicted on These Healthcare Names: BeOne Medicines (NASDAQ: ONC) and Doximity (NYSE: DOCS)
Truist Financial Analyst forecast on DE:49BA
Gregory Renza
Truist Financial
Truist Financial
€365.72→€367.48
Buy
15.56%
Upside
Reiterated
08/06/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cencora (NYSE: COR), American Well (NYSE: AMWL) and BeOne Medicines (NASDAQ: ONC)
Morgan Stanley Analyst forecast on DE:49BA
Sean Laaman
Morgan Stanley
Morgan Stanley
€347.26→€356.05
Buy
11.96%
Upside
Reiterated
08/06/26
BeOne Medicines: Buy Rating Reiterated on Strong Q2 Beat, Raised 2026 Outlook and Unchanged $395 Price Target
Citi Analyst forecast on DE:49BA
Yigal Nochomovitz
Citi
Citi
€398.25→€409.67
Buy
28.83%
Upside
Assigned
08/06/26
Analyst Lifts BeOne Medicines Price Target to $466 on Robust BRUKINSA Growth and Pipeline Milestones
Wells Fargo Analyst forecast on DE:49BA
Yanan Zhu
Wells Fargo
Wells Fargo
€351.65
Buy
10.58%
Upside
Reiterated
08/06/26
Wells Fargo Remains a Buy on BeOne Medicines (ONC)
Bank of America Securities Analyst forecast on DE:49BA
David Li
Bank of America Securities
Bank of America Securities
€354.99→€371.87
Buy
16.94%
Upside
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (NASDAQ: RVMD), Steris (NYSE: STE) and BeOne Medicines (NASDAQ: ONC)
Citizens JMP Analyst forecast on DE:49BA
Reni Benjamin
Citizens JMP
Citizens JMP
€348.14→€356.05
Buy
11.96%
Upside
Reiterated
08/06/26
BeOne Medicines price target raised to $405 from $396 at CitizensBeOne Medicines price target raised to $405 from $396 at Citizens
Guggenheim Analyst forecast on DE:49BA
Michael Schmidt
Guggenheim
Guggenheim
€369.23→€378.03
Buy
18.88%
Upside
Reiterated
08/05/26
Guggenheim Sticks to Its Buy Rating for BeOne Medicines (ONC)
TD Cowen Analyst forecast on DE:49BA
Yaron Werber
TD Cowen
TD Cowen
€372.75→€399.13
Buy
25.51%
Upside
Reiterated
08/05/26
Analysts' Top Healthcare Picks: Pennant Group (PNTG), BeOne Medicines (ONC)
J.P. Morgan Analyst forecast on DE:49BA
Jessica Fye
J.P. Morgan
J.P. Morgan
€364.84→€373.63
Buy
17.49%
Upside
Reiterated
07/23/26
BeOne Medicines price target raised to $425 from $415 at JPMorganBeOne Medicines price target raised to $425 from $415 at JPMorgan
Jefferies Analyst forecast on DE:49BA
Faisal Khurshid
Jefferies
Jefferies
€292.75→€334.07
Buy
5.05%
Upside
Upgraded
07/12/26
Analyst Reiterates Buy on BeiGene, Lifts Brukinsa-Driven Outlook and Raises Price Target to $380 Amid Pipeline Progress
Leerink Partners Analyst forecast on DE:49BA
Unknown Analyst
Leerink Partners
Not Ranked
Leerink Partners
€320→€322.64
Buy
1.46%
Upside
Reiterated
05/15/26
Leerink Partners Keeps Their Buy Rating on BeOne Medicines (ONC)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on DE:49BA
Etzer Darout
Barclays
Barclays
€357.81→€364.84
Buy
14.73%
Upside
Reiterated
09/10/26
Barclays Reaffirms Their Buy Rating on BeOne Medicines (ONC)
RBC Capital Analyst forecast on DE:49BA
Leonid Timashev
RBC Capital
RBC Capital
€395.61
Buy
24.41%
Upside
Reiterated
08/25/26
Analysts Offer Insights on Healthcare Companies: GE Healthcare Technologies Inc (NASDAQ: GEHC), Biogen (NASDAQ: BIIB) and BeOne Medicines (NASDAQ: ONC)
Wolfe Research Analyst forecast on DE:49BA
Kalpit Patel
Wolfe Research
Wolfe Research
€298.9→€325.28
Buy
2.29%
Upside
Assigned
08/09/26
BeOne Medicines price target raised to $370 from $340 at Wolfe ResearchBeOne Medicines price target raised to $370 from $340 at Wolfe Research
CMB International Securities Analyst forecast on DE:49BA
Jill Wu
CMB International Securities
CMB International Securities
€345→€388.85
Buy
22.28%
Upside
Reiterated
08/07/26
Analysts Conflicted on These Healthcare Names: BeOne Medicines (NASDAQ: ONC) and Doximity (NYSE: DOCS)
Truist Financial Analyst forecast on DE:49BA
Gregory Renza
Truist Financial
Truist Financial
€365.72→€367.48
Buy
15.56%
Upside
Reiterated
08/06/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cencora (NYSE: COR), American Well (NYSE: AMWL) and BeOne Medicines (NASDAQ: ONC)
Morgan Stanley Analyst forecast on DE:49BA
Sean Laaman
Morgan Stanley
Morgan Stanley
€347.26→€356.05
Buy
11.96%
Upside
Reiterated
08/06/26
BeOne Medicines: Buy Rating Reiterated on Strong Q2 Beat, Raised 2026 Outlook and Unchanged $395 Price Target
Citi Analyst forecast on DE:49BA
Yigal Nochomovitz
Citi
Citi
€398.25→€409.67
Buy
28.83%
Upside
Assigned
08/06/26
Analyst Lifts BeOne Medicines Price Target to $466 on Robust BRUKINSA Growth and Pipeline Milestones
Wells Fargo Analyst forecast on DE:49BA
Yanan Zhu
Wells Fargo
Wells Fargo
€351.65
Buy
10.58%
Upside
Reiterated
08/06/26
Wells Fargo Remains a Buy on BeOne Medicines (ONC)
Bank of America Securities Analyst forecast on DE:49BA
David Li
Bank of America Securities
Bank of America Securities
€354.99→€371.87
Buy
16.94%
Upside
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (NASDAQ: RVMD), Steris (NYSE: STE) and BeOne Medicines (NASDAQ: ONC)
Citizens JMP Analyst forecast on DE:49BA
Reni Benjamin
Citizens JMP
Citizens JMP
€348.14→€356.05
Buy
11.96%
Upside
Reiterated
08/06/26
BeOne Medicines price target raised to $405 from $396 at CitizensBeOne Medicines price target raised to $405 from $396 at Citizens
Guggenheim Analyst forecast on DE:49BA
Michael Schmidt
Guggenheim
Guggenheim
€369.23→€378.03
Buy
18.88%
Upside
Reiterated
08/05/26
Guggenheim Sticks to Its Buy Rating for BeOne Medicines (ONC)
TD Cowen Analyst forecast on DE:49BA
Yaron Werber
TD Cowen
TD Cowen
€372.75→€399.13
Buy
25.51%
Upside
Reiterated
08/05/26
Analysts' Top Healthcare Picks: Pennant Group (PNTG), BeOne Medicines (ONC)
J.P. Morgan Analyst forecast on DE:49BA
Jessica Fye
J.P. Morgan
J.P. Morgan
€364.84→€373.63
Buy
17.49%
Upside
Reiterated
07/23/26
BeOne Medicines price target raised to $425 from $415 at JPMorganBeOne Medicines price target raised to $425 from $415 at JPMorgan
Jefferies Analyst forecast on DE:49BA
Faisal Khurshid
Jefferies
Jefferies
€292.75→€334.07
Buy
5.05%
Upside
Upgraded
07/12/26
Analyst Reiterates Buy on BeiGene, Lifts Brukinsa-Driven Outlook and Raises Price Target to $380 Amid Pipeline Progress
Leerink Partners Analyst forecast on DE:49BA
Unknown Analyst
Leerink Partners
Not Ranked
Leerink Partners
€320→€322.64
Buy
1.46%
Upside
Reiterated
05/15/26
Leerink Partners Keeps Their Buy Rating on BeOne Medicines (ONC)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
LFMDLifeMD
ORKAOruka Therapeutics
ACHVAchieve Life Sciences
PLSEPulse Biosciences
PMNProMIS Neurosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BeOne Medicines

3 Months
David LiBank of America Securities
Success Rate
7/9 ratings generated profit
78%
Average Return
+10.02%
Copying David Li's trades and holding each position for 3 Months would result in 77.78% of your transactions generating a profit, with an average return of +10.02% per trade.
1 Year
Jessica FyeJ.P. Morgan
Success Rate
13/13 ratings generated profit
100%
Average Return
+36.43%
Copying Jessica Fye's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +36.43% per trade.
2 Years
Jessica FyeJ.P. Morgan
Success Rate
13/13 ratings generated profit
100%
Average Return
+55.44%
Copying Jessica Fye's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +55.44% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

49BA Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
0
6
6
6
0
Buy
24
22
25
25
22
Hold
2
1
1
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
26
29
32
31
22
In the current month, 49BA has received 22 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 49BA average Analyst price target in the past 3 months is 369.44.
Each month's total comprises the sum of three months' worth of ratings.

49BA Financial Forecast

49BA Earnings Forecast

Next quarter’s earnings estimate for 49BA is €1.67 with a range of €1.38 to €2.41. The previous quarter’s EPS was €1.80. 49BA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 49BA has Performed in-line its overall industry.
Next quarter’s earnings estimate for 49BA is €1.67 with a range of €1.38 to €2.41. The previous quarter’s EPS was €1.80. 49BA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 49BA has Performed in-line its overall industry.

49BA Sales Forecast

Next quarter’s sales forecast for 49BA is €1.54B with a range of €1.50B to €1.59B. The previous quarter’s sales results were €1.50B. 49BA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 49BA has Performed in-line its overall industry.
Next quarter’s sales forecast for 49BA is €1.54B with a range of €1.50B to €1.59B. The previous quarter’s sales results were €1.50B. 49BA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 49BA has Performed in-line its overall industry.

49BA Stock Forecast FAQ

What is DE:49BA’s average 12-month price target, according to analysts?
Based on analyst ratings, BeOne Medicines’s 12-month average price target is 369.44.
    What is DE:49BA’s upside potential, based on the analysts’ average price target?
    BeOne Medicines has 16.18% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is BeOne Medicines a Buy, Sell or Hold?
          BeOne Medicines has a consensus rating of Strong Buy, which is based on 14 buy ratings, 0 hold ratings and 0 sell ratings.
            What is BeOne Medicines’s share price target?
            The average share price target for BeOne Medicines is 369.44. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €409.67 ,and the lowest forecast is €325.28. The average share price target represents 16.18% Increase from the current price of €318.
              What do analysts say about BeOne Medicines?
              BeOne Medicines’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.
                How can I buy shares of BeOne Medicines?
                To buy shares of DE:49BA, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.